CommercialPrior AuthMedium impact
Multiple Sclerosis Prior Authorization Updates
Blue Cross Blue Shield of Kansas·KS · Neurology·Prior Authorization
Effective date
Mar 1, 2022
We identified it
Jun 19, 2026
Summary
Blue Cross Blue Shield of Kansas eliminated prior authorization requirements for generic Copaxone (glatiramer) and generic Tecfidera (dimethyl fumarate) effective March 1, 2022. Brand-name versions and off-label dosing still require prior authorization.
Action Required
Immediately: Billing team must update prior authorization workflows to exclude generic glatiramer and dimethyl fumarate from PA requirements for BCBSKS patients. Update billing system rules to continue requiring PA for brand-name Copaxone and Tecfidera, and for any dosing that exceeds FDA labeling. Train staff on distinction between generic and brand formulations.